Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredient Iron Carboxymaltose Iil

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the Active Ingredient Fingolimod (0.5 Mg)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Open House Original Discount Contracts 2023-03

Open Framework Agreement on Drug Discounts in Accordance with § 130A Paragraph 8 Sgb V with the Option to Join at any Time, So-Called Approval Model 2023-03

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Formoterol, Budesonide, Atc Code: R03ak07 for the Period from April 1St, 2023 to March 31St, 2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Oxybutynin, Atc Code: G04bd04 for the Period from April 1St, 2023 to March 31St, 2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Infliximab, Atc Code: L04ab02 for the Period from April 1St, 2023 to March 31St, 2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Xylometazoline, Atc Code: R01aa07 for the Period from April 1St, 2023 to March 31St, 2025